mAbs

Article	Citations
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation	923415346
Antibodies to watch in 2021	232
Antibodies to watch in 2022	227
Antibodies to watch in 2023	99
Targeting cancer with antibody-drug conjugates: Promises and challenges	82
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	50
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	49
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	48
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	47
Developments and opportunities in continuous biopharmaceutical manufacturing	39
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	35
In silico proof of principle of machine learning-based antibody design at unconstrained scale	35
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	35
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	32
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	31
A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	31
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	31
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	31
Coming together at the hinges: Therapeutic prospects of IgG3	31
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	30
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	27
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	26
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	26
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	26
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	24

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies	24
Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope	24
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody	23
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	23
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis	22
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	22
Highly sensitive detection of antibody nonspecific interactions using flow cytometry	22
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2	21
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	21
Impact of IgG subclass on molecular properties of monoclonal antibodies	21
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV	20
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	19
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics	19
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models	18
Assessing developability early in the discovery process for novel biologics	18
Current strategies for detecting functional convergence across B-cell receptor repertoires	18
Enhancing the multi-attribute method through an automated and high-throughput sample preparation	18
Ensembles in solution as a new paradigm for antibody structure prediction and design	18
Data mining patented antibody sequences	18
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies	18
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	17
In silico prediction of post-translational modifications in therapeutic antibodies	17
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	17
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters	17
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo	16
Predicting antibody binders and generating synthetic antibodies using deep learning	16
A non-clinical comparative study of IL-23 antibodies in psoriasis	16
Versatile and rapid microfluidics-assisted antibody discovery	16
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	15
Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics	15
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings	15
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	15
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities	15
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein	14
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	14
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies	14
Development of QSAR models for in silico screening of antibody solubility	13
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics	13
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	13
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351	13
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions	13
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL	13
Protective antibodies against human parainfluenza virus type 3 infection	13
Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties	12
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice	12
Challenges in antibody structure prediction	12
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	12
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention	11
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	11
Animal- versus in vitro-derived antibodies: avoiding the extremes	11

The therapeutic potential of sialylated Fc domains of human IgG	11
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	11
Stability of a high-concentration monoclonal antibody solution produced by liquid–liquid phase separation	11
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	11
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells	11
Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry	11
Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments	11
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer	11
Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion	10
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	10
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	10
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response	10
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	10
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	10
Rational selection of building blocks for the assembly of bispecific antibodies	10
Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants	10
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors	10
Improved therapeutic index of an acidic pH-selective antibody	10
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer	10
Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering	10
Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names	9
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants	9
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	9
An integrated approach for characterizing immunogenic responses toward a bispecific antibody	9
Blueprint for antibody biologics developability	9
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity	9
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	9
Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies	9
Upstream cell culture process characterization and in-process control strategy development at pandemic speed	9
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	9
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	9
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model	8
Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys	8
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL	8
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	8
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein	8
Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control	8
High concentration formulation developability approaches and considerations	8
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics	8
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	7
Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control	7
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	7
Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells	7
The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa	7
Accurate determination of epitope for antibodies with unknown 3D structures	7
Host cell protein detection gap risk mitigation: quantitative IAC-MS for ELISA antibody reagent coverage determination	7
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	7
Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana	7
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	7
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model	7
A glyco-engineering approach for site-specific conjugation to Fab glycans	6
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	6
Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies	6
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	6
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy	6
Evolution of phage display libraries for therapeutic antibody discovery	6
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	6
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	6
Development of T-cell engagers selective for cells co-expressing two antigens	6
Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein	6
David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors	6
Structural and functional characterization of a monoclonal antibody blocking TIGIT	6
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3	6
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms	6
Agonistic nanobodies and antibodies to human VISTA	5
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	5
Exploration of the antibody–drug conjugate clinical landscape	5
Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction	5
Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift	5
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	5
Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries	5
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	5
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	5
In silico high throughput mutagenesis and screening of signal peptides to mitigate N-terminal heterogeneity of recombinant monoclonal antibodies	5
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	5
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency	5
Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding	5
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	5
A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies	4
The eIg technology to generate Ig-like bispecific antibodies	4

Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	4
Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks	4
Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody	4
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models	4
Extending the capabilities of intact-mass analyses to monoclonal immunoglobulins of the E-isotype (IgE)	4
Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes	4
A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers	4
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics	4
Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting	4
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	4
Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment	4
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	4
“Stapling” scFv for multispecific biotherapeutics of superior properties	4
Mechanistic insights into the rational design of masked antibodies	4
Engineering death resistance in CHO cells for improved perfusion culture	4
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	4
Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics	4
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	4
Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX	4
Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX	4
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	4
The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance	4
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	4
CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies	4
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties	4